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ABSTRACT
Equine rhinitis A virus (ERAV) is a picornavirus associated with respiratory disease in horses and is genetically closely related to
foot-and-mouth disease virus (FMDV), the prototype aphthovirus. ERAV has recently gained interest as an FMDV alternative
for the study of aphthovirus biology, including cell entry and uncoating or antiviral testing. As described for FMDV, current
data support that acidic pH inside cellular endosomes triggers ERAV uncoating. In order to provide further insights into aph-
thovirus uncoating mechanism, we have isolated a panel of ERAVmutants with altered acid sensitivity and that differed on their
degree of sensitivity to the inhibition of endosome acidification. These results provide functional evidence of the involvement of
acidic pH on ERAV uncoating within endosomes. Remarkably, all amino acid substitutions found in acid-labile or acid-resistant
ERAVs were located in the capsid protein VP3, indicating that this protein plays a pivotal role for the control of pH stability of
the ERAV capsid. Moreover, all amino acid substitutions mapped at the intraprotomer interface between VP3 and VP2 or be-
tween VP3 and the N terminus of VP1. These results expand our knowledge on the regions that regulate the acid stability of aph-
thovirus capsid and should be taken into account when using ERAV as a surrogate of FMDV.
IMPORTANCE
The viral capsid constitutes a sort of dynamic nanomachine that protects the viral genome against environmental assaults while
accomplishing important functions such as receptor attachment for viral entry or genome release. We have explored the molecu-
lar determinants of aphthovirus capsid stability by isolating and characterizing a panel of equine rhinitis A virus mutants that
differed on their acid sensitivity. All the mutations were located within a specific region of the capsid, the intraprotomer inter-
face among capsid proteins, thus providing new insights into the regions that control the acid stability of aphthovirus capsid.
These findings could positively contribute to the development of antiviral approaches targeting aphthovirus uncoating or the
refinement of vaccine strategies based on capsid stabilization.
Equine rhinitis A virus (ERAV) is a picornavirus associatedwithfebrile respiratory disease in horses (1, 2). Due to its physical
properties and its identification as a respiratory pathogen, ERAV
was historically classified into the genus Rhinovirus (former
Equine rhinovirus-1) of the family Picornaviridae (1). However,
because of its resemblance at the nucleotide sequence level and at
the genomic structure to foot-and-mouth disease virus (FMDV),
ERAV has been reclassified into the Aphthovirus genus (3). Con-
sistently, ERAV is now considered the phylogenetically most
closely related virus to FMDV, which actually constitutes the pro-
totype aphthovirus (http://www.ictvonline.org/virusTaxonomy
.asp). Since FMDV is an extremely contagious and pathogenic
aphthovirus that can only be manipulated in high-containment
biosafety level 3 facilities, the utilization of ERAVas a surrogate for
FMDV research has increased in recent years. In this way, ERAV is
gaining interest as a suitablemodel to study aphthovirus cell entry
and uncoating or antiviral testing (4–6). Apart from its potential
as an alternative tool for FMDV research, the plasticity of its cap-
sid hasmade of ERAV an interestingmodel virus for analyzing the
structural rearrangements of picornavirus capsids (4, 7).
The ERAVgenome consists of a positive-sense, single-stranded
RNA molecule about 7.6 kb in length (3). This RNA molecule is
enclosed within an 300-Å diameter nonenveloped icosahedral
capsid (4). ERAV capsid is built out of 60 copies of each of the four
structural proteins (VP1 to VP4) arranged into 12 pentameric
subunits. This capsid is assembled in a stepwise process: five
protomer subunits (each made of one copy of each VP) form a
stable pentameric intermediate, and 12 pentameric subunits asso-
ciate to form the capsid (8). Remarkably, ERAV capsid shares with
FMDV important physicochemical properties such as its buoyant
density in CsCl and the acid lability (9, 10). Even more, in a par-
allel manner to that described for FMDV, the acid sensitivity of
ERAV capsid is related to the mechanism for genome release dur-
ing viral entry that is triggered by the acidic pH inside cellular
endosomes (5). Nevertheless, differences exist between FMDV
and ERAV cell entry: ERAV uses sialic acid as a cellular receptor
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(11, 12), is more acid-resistant than FMDV, and disassembles via
a transient empty particle that precedes the dissociation into pen-
tameric subunits (4, 9). Conversely, FMDV capsid rapidly disso-
ciates into pentameric subunits after exposure tomildly acidic pH
(2, 13). The structure of both ERAV native particle and the un-
coating intermediate have been resolved by X-ray crystallography
providing structural information on acid-induced rearrange-
ments of the capsid (4). Besides these data, the molecular bases
that govern ERAV acid-induced dissociation and capsid stability
remain poorly understood.
Deciphering the molecular basis that define capsid stability is
important not only for the understanding of acid-induced un-
coating but also for the improvement of aphthovirus vaccines
based on empty capsids or inactivated virions (14–18). Along this
line, the analysis of picornavirus mutants with altered acid sensi-
tivities has provided valuable information to understand the
mechanism of acid-dependent uncoating and to understand the
molecular basis of capsid stability (13, 19–25). However, to our
knowledge this kind of analysis had not been previously per-
formed for ERAV.Having inmind all these considerations, in this
work we have isolated and characterized a panel of ERAVmutants
that varied on their acid resistance. The analysis of these mutants
revealed parallelisms and differences between the capsid regions
that govern acid-dependent disassembly and control capsid sta-
bility in ERAV and FMDV. Remarkably, VP3 appeared as a key
determinant of ERAV pH stability. In addition, these mutants
revealed a role of the intrasubunit interface between VP3 and VP2
or between VP3 and VP1 on acid stability. These results should be
taken into account when using ERAV as surrogate of FMDV for
the study of the molecular basis of the stability of the aphthovirus
capsid.
MATERIALS AND METHODS
Cells and viruses. Vero cells (ATCC CCL-81) were grown on Dulbecco
modified Eagle medium (DMEM; Gibco) supplemented with 5% fetal
bovine serum (Gibco), 2mM L-glutamine, and penicillin-streptomycin at
37°C in a 7% CO2 atmosphere. ERAV was kindly provided by Carol A.
Hartley (Faculty of Veterinary Sciences, The University of Melbourne).
The origin of coxsackievirus B5 (CVB5) strain Faulkner has been de-
scribed (26).
Infections and virus titrations. For infections in liquid medium, cell
monolayers were incubated with the appropriate amount of virus diluted
inDMEMwithout serum for 1 h at 37°Cwith gentle rocking every 15min.
The viral inoculumwas then removed, and fresh culturemediumcontain-
ing 5% fetal bovine serum was added. Infected cultures were incubated at
37°C and at the desired time postinfection (p.i.), infected plates were
frozen at 70°C. Virus titrations were performed by standard plaque
assay in agar semisolid medium (27). To this end, 10-fold serial dilutions
of the viral samples were added to Vero cell monolayers. After 1 h of
incubation at 37°C, viral inoculum was removed and semisolid medium
(0.5% agar, 1% fetal bovine serum, and 0.045 mg/ml DEAE-dextran in
DMEM) was added. Infected plates were incubated at 37°C, and lysis
plaques were visualized by staining with crystal violet 48 to 60 h p.i. The
multiplicity of infection (MOI) used in each experiment was expressed as
the number of PFU per cell and is indicated in the figure legends.
Acid-induced inactivation assays. A previously published protocol
used for FMDV (13) was modified for ERAV. Briefly, equal amounts of
viral samples (2 104 to 4 104 PFU) diluted in 50l of culturemedium
were mixed with 300 l of phosphate-buffered saline solutions of differ-
ent pHs for 30min at room temperature, the pHwas neutralized with 100
l of 1 M Tris (pH 7.6), and the remaining infectivity in each sample was
determined by titration in Vero cells as described above.
Inhibition of endosomal acidification with NH4Cl. Vero cell mono-
layers were treated 1 h prior to infection with 5 or 10mMNH4Cl (Merck)
in culture medium supplemented with 25 mMHEPES at pH 7.4 to buffer
extracellular pH, and the drug was maintained throughout the rest of the
infection (13).
Nucleotide sequencing. Viral RNA was extracted using TRI-Reagent
(Sigma). The nucleotide sequence of the capsid coding region of ERAV
was amplified by reverse transcription-PCR (RT-PCR), as reported pre-
viously (13, 28). The following forward (f) and reverse (r) synthetic
oligonucleotide primer pairs were used: GGCCAAACTGTGCCTGTGAC
CATG(f) and CATCTGTGTGCACGTGCATGTCCAC(r); GAGGGTTG
GATCTGTGTTGA(f) and GCTTATCGGGCAGGTCAAC(r); and CGA
TTAGAGTGGTGTCTGTG(f) and GCTCTCAACATCTCCAGCCA(r).
Automated DNA sequencing of RT-PCR products was performed by
Macrogen, Inc. (Amsterdam, The Netherlands), using the same primers.
Nucleotide sequencing confirmed that the capsid coding region of the
wild-type (WT) ERAV used in this study only exhibited one silent change
(G222T) relative to that of the crystallized ERAV capsid (GenBank acces-
sion number FJ607143).
Molecular graphics and structure analysis. The atomic coordinates
of ERAV capsid at neutral (PDB code 2WFF) and acidic pH (PDB code
2WS9) were used (4). Structures were visualized using PyMol Molecular
Graphics System version 1.5.0.4 (Schrödinger, LLC). Contact informa-
tion of selected residues was obtained using VIPERdb (29).
Data analysis. Data are presented as means  standard deviations
(SD). Analysis of variance (ANOVA) was performed using SPSS15 (SPSS,
Inc.). Bonferroni’s correction was applied for multiple comparisons. Sta-
tistically significant differences are indicated in figures by one asterisk for
a P value of0.05 or two asterisks for a P value of0.005.
RESULTS
Isolation and characterization of NH4Cl-resistant ERAVs. Due
to its acid-triggered uncoating mechanism the infection of ERAV
is impaired by drugs that inhibit endosomal acidification (5). Ac-
cordingly, we explored the possibility of isolating mutant ERAVs
with increased resistance to the treatment with an inhibitor of
acid-dependent uncoating. Following an approach similar to that
previously used for FMDV, we selected and characterized ERAV
mutants with increased resistance to the inhibition of endosomal
acidification exerted by NH4Cl (13, 22). NH4Cl-resistant ERAVs
were isolated by biological cloning in Vero cells infected with
ERAV in semisolid agar medium containing 10mMNH4Cl. After
72 h of infection, Vero cell monolayers treated with NH4Cl exhib-
ited a reduction of104-fold in the number of lysis plaques pro-
duced relative to control cells, thus confirming that the drug im-
paired the infection of ERAV.Well isolated lysis plaques grown in
the presence of NH4Cl were picked and amplified by two serial
passages in liquid medium in the presence of 10 mM NH4Cl.
Three of these amplified viral clones, termedRC3,RC8, andRC19,
showed a significant increase in their resistance to treatment with
5 mM NH4Cl compared to the parental wild-type (WT) ERAV
(Fig. 1A). Thus, 5 mM NH4Cl should raise endosomal pH to a
level that is compatible with uncoating of RC3, RC8, and RC9
mutants but enough to limit the uncoating ofWT virus. However,
only RC3 and RC8 exhibited a significant resistance to 10 mM
NH4Cl, suggesting that the resilient phenotype of RC19 was
weaker than those of RC3 and RC8. Previous studies using acid
inactivation assays of FMDV have revealed that FMDV mutants
resistant to NH4Cl are more acid labile, indicating that the mech-
anism of escape from the inhibitory effect of this drug is based on
the elevation of pH-threshold for uncoating (13, 22). When the
acid sensitivity of the infectious virions was compared using an
Caridi et al.
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acid-induced inactivation assay, the three mutants proved to be
more acid sensitive than the parental WT ERAV (Fig. 1B). Inter-
estingly, the three viruses showed similar acid inactivation pro-
files, although RC19 was less sensitive to acid inactivation at a pH
slightly below 6. This result is consistent with the differences ob-
served in the sensitivity to NH4Cl treatment of these mutants,
further supporting a correlation between resistance to NH4Cl and
acid sensitivity. In these experiments the enterovirus CVB5 was
included as a control picornavirus with a capsid that is stable over
a wide pH range (Fig. 1B). As expected, CVB5 did not show any
loss of infectivity within the pH range analyzed. Overall, these
results are consistent with the hypothesis that the increase in re-
sistance to the inhibition of endosomal acidification exerted by
NH4Cl is mediated by an increase in the acid sensitivity of the
virion.
Isolation and characterization of acid-resistant ERAVs.
Since NH4Cl-resistant ERAVs displayed more acid-sensitive viri-
ons than those of the WT, we decided to evaluate the opposite
situation. That is, if, as reported for FMDV (23, 24), ERAV mu-
tants with increased acid resistance displayed augmented sensitiv-
ity to NH4Cl. Hence, as described for FMDV (24, 25, 30), ERAV
mutants with increased acid resistance were isolated after serial
passages preceded by acid treatment. For this purpose, 106 PFU of
WT virus were incubated at pH 5.0 for 1 h. Then, pHwas neutral-
ized, samples were added to Vero cells, and infection was allowed
to proceed in liquid medium. When cytopathic effect was ob-
served (about 48 h p.i.) viruses were harvested. Rounds of this acid
treatment/infection procedure were conducted in two indepen-
dent series carried out in parallel (termed Res1 and Res2). After 10
serial passages, the acid sensitivity of the resultant populationswas
analyzed (Fig. 2A). Both Res1 and Res2 showed a significant in-
crease in acid resistance (pH 5.0) compared to WT ERAV, which
confirmed the selection of viruses with increased acid resistance in
these populations. When the sensitivity to the inhibition of endo-
somal acidification using NH4Cl was analyzed, both Res1 and
Res2 displayed a significant increase in the sensitivity to NH4Cl in
comparison to WT ERAV (Fig. 2B). These results confirmed our
initial hypothesis and provided additional evidence supporting
the connection between stability of the capsid at acidic pH and
sensitivity of ERAV to NH4Cl.
Molecular basis for the different acid sensitivity of ERAV
mutants.The complete nucleotide sequences of the capsid coding
regions of acid-sensitive (NH4Cl-resistant) mutants RC3, RC8,
and RC19, as well as that of acid-resistant (NH4Cl-sensitive) mu-
tants Res1 and Res2 used in the experiments were determined and
FIG 1 ERAV mutants with increased resistance to NH4Cl display enhanced
acid lability. (A) Analysis of NH4Cl sensitivity of ERAV mutants RC3, RC8,
and RC19. Monolayers of Vero cells treated or not treated with NH4Cl were
infected (MOI of 0.5 PFU/cell) with themutants and the parental ERAV (WT).
Virus yield was determined 24 h p.i. by a standard plaque assay. (B) Acid
sensitivity of NH4Cl-resistant ERAVs. Equal amounts of the different viruses
were treated with acid buffers of different pHs for 30 min, neutralized, and
plated. Infectivity was calculated as the percentage of PFU recovered relative to
that obtained at pH 7.1. One asterisk indicates a P value of0.05; two asterisks
indicate a P value of0.005.
FIG2 ERAVmutants with increased acid resistance display enhanced sensitivity to endosomal acidification blockage exerted byNH4Cl. (A) Equal PFU amounts
of the parental ERAV (WT) and the mutants Res1 and Res2 (isolated after serial passages preceded by acid treatments) were incubated with acid (pH 5.0) or
neutral (pH 7.4) buffers for 30 min, neutralized, and plated on Vero monolayers. Infectivity was calculated as the percentage of PFU recovered relative to that
obtained at pH 7.4. (B) Analysis of NH4Cl sensitivity of ERAVmutants Res1 and Res2. Monolayers of Vero cells treated or not treated with NH4Cl were infected
(MOI of 0.5 PFU/cell) with the mutants and the parental ERAV, and the virus yield was determined at 24 h p.i. One asterisk indicates a P value of0.05; two
asterisks indicate a P value of0.005.
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compared to that of WT virus (Table 1). The viral populations
RC3, RC8, and RC19 sequenced corresponded to the viral stocks
produced after two serial passages in the presence of 10 mM
NH4Cl. The viral populations Res1 and Res2 sequenced were
those recovered after 10 serial rounds of acid treatment and infec-
tion. Each of the five mutant ERAVs displayed a single nonsyn-
onymous nucleotide substitution in the consensus sequence of the
capsid compared to that ofWT virus. Apart from the nonsynony-
mous replacements, mutant RC19 showed an additional silent
mutation in the capsid coding region. All of the substitutions
found led to nucleotide transitions, except the one found in mu-
tant RC3 that was a transversion. Remarkably, all the amino acid
replacements selectedwere located inVP3protein. The nucleotide
substitutions found in the three acid-sensitive mutants were dif-
ferent and led to amino acid replacements VP3 F53Y, R203C, and
I109V in RC3, RC8, and RC19, respectively. On the other hand,
the two acid-resistant viruses (Res1 and Res2) selected from two
individual passage series had acquired a common nucleotide sub-
stitution that introduced amino acid replacement VP3 N105S
(Table 1). The analysis of the sequence of earlier passages of Res1
and Res2 revealed that this substitution was already dominant at
passages 6 and 7 for Res1 and Res2, respectively. Although the
selection of the same mutation in an independent passage series
could be considered surprising, there are precedents for the inde-
pendent selection of common amino acid replacements increas-
ing acid resistance of Aphthovirus capsid (21, 23–25). This could
be the result of selective constraints that arise during the isolation
of this kind ofmutants that favor the selection of substitutionVP3
N105S.
All the amino acid substitutions found in the acid-resistant and
-sensitive mutants affected highly conserved residues in VP3 pro-
tein, which were invariant in the 25 different VP3 sequences avail-
able at GenBank from ERAV isolated in different dates and loca-
tions. Moreover, all the substitutions found in RC3, RC8, RC19,
and Res2 (selected as a model for acid-resistant ERAV since Res1
and Res2 carried the same replacement) were stable after 10 serial
passages in the absence of selective pressure. These amino acid
substitutions were mapped on the crystal structures reported for
ERAV capsid at neutral pH and for its empty particle at low pH
(Fig. 3A and B). All of the replacements of acid-sensitive mutants
(R203C, I109V, and F53Y) were found aligned at the intraproto-
meric interface between VP2 and VP3. In addition, replacement
N105S, found in acid-resistant ERAVs, was located close to these
residues, at the intraprotomeric interface between VP3 and VP1.
At neutral pH all of these residues appeared very close to the N
terminus of VP1, which was displaced from this position at low
pH (compare discontinuous circles between left and right panel in
Fig. 3A andB).Moreover, all the amino acid substitutions affected
residues that established interactions with other residues from
VP2 and, to a lesser extent, with the N terminus of VP1 (Table 2),
a capsid region involved in acid-induced rearrangements required
for uncoating (4). Some of the interactions of the mutated resi-
dues were conserved at neutral and acidic pH, whereas other
changed, suggesting that the four residues affected by the muta-
tions (F53, N105, I109, and R209) were involved in acid-induced
rearrangements of the viral capsid. Accordingly, the introduction
of the replacements found in our mutants would probably alter
this interaction pattern modulating the stability of the capsid at
acidic pH.Overall, the fact that all the nonsynonymousmutations
found in acid-sensitive and acid-resistant mutants were located in
the coding region of VP3 indicates that this protein, and specifi-
cally its interface with VP2 and VP1, plays a pivotal role for the
control of pH stability of ERAV capsid.
Fitness of ERAVmutants with altered acid sensitivity. In or-
der to estimate the potential fitness cost derived from the mu-
tations found in acid-sensitive and acid-resistant ERAVs, we
analyzed the plaque size and the growth kinetics of the mutant
virus in Vero cells. The phenotype of plaque size of all ERAV
mutants was similar to that of WT virus (Fig. 4A). In addition,
no major differences in the viral growth kinetics of the viruses
were noticed when single-step growth curves were conducted
(Fig. 4B). Taken together, these results suggested that the mu-
tations selected in acid-sensitive and acid-resistant ERAVs did
not severely affect the growth ability of the virus in cultured
cells.
DISCUSSION
The capsid protects the viral genome against environmental as-
saults and also accomplishes vital functions, such as receptor at-
tachment for viral entry or genome release (31). In this way, viral
capsids constitute dynamic nanomachines that can undergo dra-
matic rearrangements during the different steps of the virus life
cycle to achieve these functions (32, 33). For instance, genomic
RNA must be able to leave the capsid to initiate a new round of
infection, making uncoating a crucial step of the virus life cycle
that provides an interesting target for antiviral design (34–39).
Thus, understanding the molecular basis that govern these transi-
tions and define capsid stability is of outstanding interest to deci-
pher the biology of viral pathogens, as well as for the development
of antiviral strategies and vaccine improvement. Considering that
ERAV is becoming a model for the analysis of aphthovirus biol-
ogy, we have explored themolecular basis controlling pH stability
of this virus. To this end, and going one step ahead with the work
made with FMDV, we have isolated and characterized a panel of
ERAV mutants differing on their acid sensitivity. Overall, our re-
sults are consistent with the hypothesis that the increase in resis-
tance to inhibition of endosomal acidification exerted byNH4Cl is
mediated by an elevation of uncoating pH. In addition, the oppo-
site effect was observed for acid-resistant mutants, which showed
an increase in the sensitivity to inhibition of endosomal acidifica-
tion exerted by NH4Cl. These results provided further func-
tional evidence of the link between uncoating mechanism and
acidic pH inside cellular endosomes (5). The ERAV mutants
with altered pH stability that we isolated showed plaque sizes
TABLE 1Mutations selected in the capsid coding regions of ERAV
mutants with different acid sensitivities
Phenotype Mutant








RC3 T1088A VP3 F53Y
RC8 C1537T VP3 R203C




Res1 A1244G VP3 N105S
Res2 A1244G VP3 N105S
a Numbering as for the ERAV capsid (GenBank accession number FJ607143).
Caridi et al.
9728 jvi.asm.org November 2016 Volume 90 Number 21Journal of Virology
and growth kinetics similar to those of theWT virus, suggesting
that, as in the case of FMDV, the selection of viruses with
altered acid stability, including those that were acid resistant,
can be performed with a low fitness cost in vitro (13, 21–25).
This is supported by the stability of these amino acid substitu-
tions noticed after 10 serial passages of the mutants in the
absence of selective pressure. Nevertheless, it cannot be ex-
cluded that these replacements could lead to detrimental ef-
fects in vivo, as described for FMDV (40). In fact, it is conceiv-
able that WT ERAV has evolved an optimal pH for uncoating
and that displacement of this value could result in attenuation
in vivo.
Interestingly, all the amino acid replacements found in ERAV
FIG 3 Location of mutations affecting acid stability of ERAV. (A) Inside schematic view of a pentameric subunit in the capsid of ERAV at neutral (left panel) or
acid pH (right panel) displaying the location of amino acid residues found to be substituted in mutants (spheres). The position of a single protomer is indicated
by gray lines. Discontinuous circles indicate the location of the N terminus of VP1. Only amino acid main chains are shown for clarity. The atomic coordinates
of ERAV capsid at neutral (PDB code 2WFF) and acidic pH (PDB code 2WS9) were used (4). (B) Cartoon representation of the protomer highlighted in panel
A showing the position of the amino acid replacements found in ERAVmutants at neutral (left) or low (right) pH. Circles indicate the location of theN terminus
of VP1. The positions of 5- and 3-fold symmetry axes are denoted by pentagons and triangles, respectively. VP1 is green, VP2 is magenta, VP3 is cyan, and VP4
is yellow.
TABLE 2 Contacts established by capsid residues mutated in ERAVs
with altered pH stability
VP3 residue
Capsid residues establishing contact with the VP3
residuea
Neutral pH Low pH
F53 VP2 Y152, S156, L199 VP2 S156, L162, L199
N105 VP1 T13
I109 VP2 L162, N164 VP1 G5 VP2 L162, N164
R209 VP2 S121, S200, E201, T203 VP2 S200, E201, T203
a Contact information was retrieved from VIPERdb (29). Contacts that vary between
neutral- and low-pH structures are indicated in boldface.
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mutants with different acid stability were mapped in VP3. The
detailed examination of the mutated residues indicated did not
reveal a common side chain substitution pattern. Acid-sensitive
mutants RC3 and RC19 introduced amino acid replacements that
preserved hydrophobicity (F53Y and I109V), in one case display-
ing a bulkier residue with the introduction of a hydroxyl group
(F53Y) and in the other case a smaller one (I109V). On the other
hand, the acid-sensitive mutant RC8 displayed a loss of positive
charge and the introduction of a smaller residue (R203C). Inter-
estingly, substitution R209C abolished a positive charge that in-
teractedwith the negatively chargedVP2 E201, suggesting that the
loss of the electrostatic charge of this residue mediates the mech-
anism of action of this mutant. In the case of the acid-resistant
viruses Res1 and Res2, the replacement selected maintains a polar
residue but with a smaller side chain (N105S). N105, I109, and
R203 were located in -strands of the capsid that were found at
both neutral and acidic pH (4). In FMDV,mutations also affecting
the pH stability of the capsid at residues VP3 116, 118, and 123
have been located within another -strand of VP3 (13, 22), al-
though these residues were located close to the interpentameric
interface, not at the intraprotomeric interface between VP3 and
VP2 as occurred in ERAV. In this way, ERAVmutants VP3 F53Y,
I109V, and R203C demonstrate for the first time that the interface
between VP3 and VP2within the same protomer constitutes a key
capsid region controlling pH stability. All of these residues also
map close to the N terminus of VP1 in the native ERAV particle.
Even more, replacement VP3 N105S is located at the interface
between VP3 and the N terminus of VP1, and replacement VP3
I109V also affected an amino acid interacting with the N terminus
of VP1 at neutral pH. Both interactions are lost in the empty
particle as a results of exposure to acidic pH. This is consistent
with structural data supporting that the N terminus of VP1 is key
for aphthovirus uncoating and undergoes a profound rearrange-
ment during the transition between the virion to the low-pH
empty particle uncoating intermediate (4). Thus, these data fur-
ther support the importance of the N terminus of VP1 in regulat-
ing the pH stability of aphthovirus capsid, as previously docu-
mented for FMDV by the selection of amino acid replacements in
theN terminus of FMDVVP1 (22–25). Remarkably, the involve-
ment of the N terminus of VP1 in uncoating is a conserved
feature within the Picornaviridae family (41–43). The relevance
of the intraprotomeric interface between VP3 and VP2 on aph-
thovirus pH stability had not been previously assessed, since
FMDV pH stability was mainly associated with the N terminus of
VP1 and the residues located at the pentameric interface (13, 21–
25, 44–46). However, independent studies have shown that acid
resistant FMDVs from different serotypes display a common
amino acid substitution (VP2H145Y) in a residue located close to
the center of the protomer and the interface betweenVP3 andVP2
and that interacted with the N terminus of VP1 (21, 24). All of
these data are consistent with the involvement of the contacts
amongVP3,VP2, andVP1 in the central region of the protomer in
the regulation of aphthovirus acid stability. Considering the im-
portance for capsid stability of the intersubunit interactions (ei-
ther interprotomeric or interpentameric) documented for FMDV
(14, 47), the identification in this study of the intraprotomeric
interface as an important regulator of ERAV capsid expands the
regions that govern aphthovirus capsid stability.
As commented above, all of the replacements found in ERAV
mutants were located in VP3, which is the most conserved of the
structural proteins between ERAV and FMDV (4). However, the
different locations of pH-altering mutations in FMDV and ERAV
capsids could reflect differences between FMDV and ERAV un-
coating. In fact, ERAV uncoating is produced by a stable transient
empty particle intermediate, while the experimental evidence for
this intermediate is scarce in the case of FMDV (48). Hence, the
current model for FMDV uncoating supports its rapid dissocia-
tion into pentameric subunits after exposure to mildly acidic pH
(13, 49). The parallelism between pH mutants of ERAV and
FMDV (the involvement of VP3 and connections with the VP1 N
terminus) is consistent with the hypothesis of a common ancestral
mechanism for aphthovirus uncoating (4), but the differences in
the location of themutations support the specialization and diver-
sification of ERAV and FMDV uncoating mechanisms as a prod-
uct of viral evolution.
In summary, we provide novel evidence that VP3 and espe-
cially the intrasubunit region that forms the interface among VP3,
VP2, and VP1 within the same protomer, is a key regulator of the
pH stability of ERAV capsid. These results expand our knowledge
of the regions involved in the regulation of aphthovirus capsid
stability and could contribute to the improvement of vaccine
strategies based on capsid stabilization that are currently being
addressed.
FIG 4 Fitness analysis of ERAVmutants with altered acid sensitivity. (A) Lysis
plaques of the parental ERAV (WT), acid-sensitive ERAVmutants (RC3, RC8,
and RC19) and acid-resistant ERAVmutants (Res1 and Res2). Vero cells were
infected in semisolid agar medium, and plaques were visualized by staining
with crystal violet at 60 h p.i. (B) Single-step growth curve analysis of ERAVs
indicated in panel A. Vero cells were infected (MOI of 1 PFU/cell), and the
virus titers in the supernatants were determined by plaque assay at different
times postinfection.
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